The drug has been approved by NMPA to initiate Phase 2 clinical trials for osteoarthritis, becoming the first EP4 antagonist in China for a disease-modifying therapy of OA. Pre-clinical results demonstrated its multiple effects, including analgesic, anti-inflammatory, and cartilage regenerative properties, highlighting its significant potential as a disease-modifying therapeutic approach for osteoarthritis.

Back to List